BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

PHASE3CompletedINTERVENTIONAL
Enrollment

1,057

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

October 31, 2008

Conditions
HIV Infections
Interventions
DRUG

ATV

300mg Oral capsules for 96 weeks

DRUG

RTV

100mg Oral Capsules for 96 weeks

DRUG

Tenofovi-Emtricitabine (TDF/FTC) tablet

One tablet with 300 mg - 200 mg once a day for 96 weeks.

DRUG

LPV

400 mg (3 133mg capsules) BID for 96 weeks

Trial Locations (79)

Unknown

Local Institution, Phoenix

Local Institution, Laguna Beach

Local Institution, Washington D.C.

Local Institution, Fort Lauderdale

Local Institution, Orlando

Local Institution, Huntersville

Local Institution, Dallas

Local Institution, Fort Worth

Local Institution, Capital Federal

Local Institution, Mar del Plata

Local Institution, Rosario

Local Institution, Buenos Aires

Local Institution, Córdoba

Local Institution, Darlinghurst

Local Institution, Carlton

Local Institution, South Yarra

Local Institution, Vienna

Local Institution, Bruges

Local Institution, Ghent

Local Institution, Curitiba

Local Institution, Recife

Local Institution, Campinas

Local Institution, Rio de Janeiro

Local Institution, São Paulo

Local Institution, Toronto

Local Institution, Montreal

Local Institution, Viña del Mar

Local Institution, Santiago

Local Institution, Bogotá

Local Institution, San José

Local Institution, Santo Domingo

Local Institution, Nice

Local Institution, Paris

Local Institution, Villejuif

Local Institution, Berlin

Local Institution, Bonn

Local Institution, Cologne

Local Institution, Hamburg

Local Institution, Guatemala City

Local Institution, Kowloon

Local Institution, Jakarta

Local Institution, Genova

Local Institution, Milan

Local Institution, Roma

Local Institution, Torino

Local Institution, Guadalajara

Local Institution, Zapopal

Local Institution, Zapopan

Local Institution, Mexico City

Local Institution, Chihuaha

Local Institution, Durango

Local Institution, San Luis Potisi

Local Institution, Maastricht

Local Institution, Utrecht

Local Institution, Panama City

Local Institution, Lima

Local Institution, Lisbon

Local Institution, Ponce

Local Institution, San Juan

Local Institution, Singapore

Local Institution, Port Elizabeth

Local Institution, Bloemfontein

Local Institution, Johannesburg

Local Institution, Meadowdale

Local Institution, Westdene

Local Institution, Durban

Local Institution, Mowbray

Local Institution, Parow

Local Institution, Rugby

Local Institution, Barcelona

Local Institution, Córdoba

Local Institution, Madrid

Local Institution, Málaga

Local Institution, Kaohsiung City

Local Institution, Taipei

Local Institution, Chiang Mai

Local Institution, Khonkaen

Local Institution, London

Local Institution, Manchester

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00272779 - BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada | Biotech Hunter | Biotech Hunter